PREDICTIVE ONCOLOGY INC.

91 43rd Street, Suite 110

Pittsburgh, PA 15201

 

May 20, 2024

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attention: Ms. Jane Park, Staff Attorney

 

Re:	Predictive Oncology Inc.
	Acceleration Request for Registration Statement on Form S-3, as amended
	File No. 333-279123
	Requested Date: May 21, 2024
	Requested Time: 5:00 P.M. Eastern Time

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Predictive Oncology Inc. (the “Registrant”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-279123) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request (the “Registration Statement Acceleration Request”) via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). The Registrant hereby authorizes Alan Seem of DLA Piper LLP (US), counsel for the Registrant, to make such request on the Registrant’s behalf.

 

We request that we be notified of the effectiveness of the Registration Statement by telephone to Alan Seem of DLA Piper LLP (US) at 650-833-2050, or in his absence, Amanda Maki of DLA Piper LLP (US) at 713-425-8461. Thank you for your assistance.

 

	Very truly yours,
	/s/ Raymond Vennare
	Raymond Vennare
	Chief Executive Officer

 

 

cc:	Raymond Vennare (Chief Executive Officer, Predictive Oncology Inc.)
	Josh Blacher (Interim Chief Financial Officer, Predictive Oncology Inc.)
	Alan. Seem (DLA Piper LLP (US))
	Amanda Maki (DLA Piper LLP (US))